Insights

From 17–19 April, the UK’s seventh biennial psychedelic conference tackled some of the field’s most urgent questions. In this second instalment, we explore the ethical dilemmas of giving psychedelics to young people, the critical role of therapist selection, how female biology affects drug interactions, the pros and cons of non-hallucinogenic psychoplastogens, and what it really means to integrate psychedelic insights.

With a psilocybin testing license now issued to Nordic Analytical Laboratories, Colorado’s regulated psychedelic supply chain appears ready to launch. Though final state-approved paperwork remains pending, advocates hope the first psilocybin sessions could take place by the end of May.

Following last summer’s FDA rejection of MDMA-assisted therapy for PTSD, veteran-led advocacy groups Healing Breakthrough and Heroic Hearts Project are uniting. In this exclusive interview, Jesse Gould and Juliana Mercer say the fight is far from over—and that healing shouldn’t require a passport.